Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
January 04, 2024 17:25 ET
|
Gradalis, Inc.
GRAD1405 uses Gradalis’ breakthrough gene silencing bi-shRNAi technology to specifically reduce the expression of certain mutated KRAS genesExisting therapies have experienced rapid drug resistance...
Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
December 05, 2023 08:00 ET
|
Gradalis, Inc.
Emerging research shows that targeting initial mutations expressed on a tumor cell surface, called clonal mutations, is critical in achieving a durable clinical benefitFor example, lung cancer...
Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
November 16, 2023 15:12 ET
|
Gradalis, Inc.
DALLAS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a leader in the development of personalized anti-cancer cellular therapies for patients with solid tumors, announced today that it has been...
Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 2023
October 18, 2023 08:00 ET
|
Gradalis, Inc.
DALLAS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer...
Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
September 28, 2023 08:00 ET
|
Gradalis, Inc.
Evidence from multiple researchers supports Vigil enhancement of clonal neoantigen effector cell response and correlation to relapse free survival and overall survival benefit Targeting clonal...
Gradalis to Participate in the Cantor Global Healthcare Conference
September 21, 2023 08:30 ET
|
Gradalis, Inc.
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, clinical stage biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian and...
Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform
June 06, 2023 16:05 ET
|
Gradalis, Inc.
Technology leverages new coating process to create 3D scaffold matrix that is designed to mimic the tumor microenvironment and enable large scale tumor cell expansionDemonstrated successful increase...
Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
March 29, 2023 16:05 ET
|
Gradalis, Inc.
DALLAS, March 29, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian...
Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's Sarcoma
March 14, 2023 08:00 ET
|
Gradalis, Inc.
-Pilot study in Ewing's Sarcoma supports the therapeutic potential of Vigil in multiple solid tumor types- -Circulating tumor DNA levels, used to monitor therapeutic response, corresponded to changes...
Gradalis to Present at the 2023 BIO CEO & Investor Conference
February 02, 2023 08:01 ET
|
Gradalis, Inc.
DALLAS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian...